Pancreatic Cancer Research

ResearcherHuaian First People’s HospitalActive in the last 2 years

Yabin Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-0504-0822; OpenAlex author ID A5055468623. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. Metabolic reprogramming shapes the immune microenvironment in pancreatic adenocarcinoma: prognostic implications and therapeutic targets. First author DOI 10.3389/fimmu.2025.1555287↗
  2. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway. Last author DOI 10.1186/s13046-023-02792-0↗
  3. Reciprocal regulation of DGCR5 and miR-320a affects the cellular malignant phenotype and 5-FU response in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.18377↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weihua Song · 1 shared paper, 2025 · strength 0.27
  2. Jiachang Chi · 1 shared paper, 2025 · strength 0.27
  3. Kai Lin · 1 shared paper, 2023 · strength 0.18
  4. Wentao Gao · 1 shared paper, 2023 · strength 0.18
  5. Yong Sun · 1 shared paper, 2017 · strength 0.07
  6. Ling Liu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.